REGENXBIO

REGENXBIO has leading, in-house end-to-end capabilities in the research, clinical development and commercial-ready manufacturing of AAV gene therapies. REGENXBIO is seeking to improve lives through the curative potential of gene therapy. That’s why we are innovating what is possible in gene therapy with the goal of delivering one-time treatments to patients living with common and rare diseases. We are developing gene therapy product candidates in the retinal, metabolic and neurodegenerative therapeutic areas. Our team of scientists and engineers are dedicated to expanding the understanding and applications of AAV vectors, applying the differentiated capabilities of the NAV® Technology Platform and exploring the potential to generate new, innovative AAV Therapeutics. We believe that what we do matters – to patients, to their families and to their communities.